{
    "nctId": "NCT04764682",
    "briefTitle": "Determining Molecular Drivers of Radiation Dermatitis",
    "officialTitle": "Determining Molecular Drivers of Radiation Dermatitis",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 20,
    "primaryOutcomeMeasure": "Change in skin",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients receiving standard-of-care postoperative radiation therapy (2-2.7 Gy per fraction) to the breast and/or chest wall for breast cancer treatment.\n* Tissue diagnosis of breast cancer.\n* Age \\> 18 years\n* Signed informed consent.\n* Complete blood count within normal limits within the preceding 2 weeks.\n\nExclusion criteria:\n\n* Induction chemotherapy or biologic therapy\n* Concurrent chemotherapy or biologic therapy\n* Autoimmune disease with skin manifestations - psoriasis, dermatomyositis, scleroderma, eczema, polymyositis\n* Allergy to lidocaine anesthesia\n* Known bleeding diathesis (anticoagulation with warfarin, coagulation/bleeding disorders, vitamin C or K deficiency, thrombocytopenia)\n* History of keloids or easy scarring",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}